CompletedNot Applicable

Identification of New Patient Stratification Tools in MSS RAS mt mCRC

Germany, Ireland29 participantsStarted 2018-09-19

Plain-language summary

This is a translational, multicentre and multinational study. The aim of this study is to identify new patient stratification tools in microsatellite stable RAS mutant metastatic Colorectal Cancer

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Ability to give signed informed consent prior to any study specific procedures and willing and able to comply with the protocol,
✓. Age ≥ 18 years,
✓. ECOG status of ≤ 2,
✓. At least 16 weeks of life expectancy at time of entry into the study.
✓. Histologically confirmed stage IV MSS RAS mt mCRC as per standard diagnostic tests,
✓. Unresectable and measurable disease (at least one measurable target lesion) as per clinical and radiologic criteria (RECIST v.1.1),
✓. No prior chemotherapy and/or radiation therapy for CRC administered in the metastatic setting,
✓. Scheduled to receive or receiving SOC chemotherapy with fluoropyrimidines and oxaliplatin +/- bevacizumab (baseline blood sample should be collected and questionnaires completed during pre-screening and before chemotherapy initiation),

Exclusion criteria

✕. Patient with CRC that has received any therapy for CRC before:
✕. surgical resection of tissue that would be utilised in this study
✕. biopsy procedure for tissue that would be utilised in this study,
✕. Patient who has received any investigational product within 28 days of the first day of palliative chemotherapy administration,
✕. Patient with any significant history of non-compliance to medical treatments or with inability to grant reliable informed consent,
✕. Patient with clinical or laboratory contraindication to receive SOC chemotherapy with fluoropyrimidines and oxaliplatin.

What they're measuring

Stratification Tools

Timeframe: 4 years

Trial details

NCT IDNCT03699111

SponsorCancer Trials Ireland

Sponsor typeNETWORK

Study typeOBSERVATIONAL

Primary completion2022-04-01

View on ClinicalTrials.gov More Advanced Colorectal Cancer trials